ImmunityBio (IBRX) Retained Earnings (2016 - 2025)
Historic Retained Earnings for ImmunityBio (IBRX) over the last 12 years, with Q3 2025 value amounting to -$3.7 billion.
- ImmunityBio's Retained Earnings fell 1157.73% to -$3.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.7 billion, marking a year-over-year decrease of 1157.73%. This contributed to the annual value of -$3.4 billion for FY2024, which is 1396.38% down from last year.
- ImmunityBio's Retained Earnings amounted to -$3.7 billion in Q3 2025, which was down 1157.73% from -$3.6 billion recorded in Q2 2025.
- In the past 5 years, ImmunityBio's Retained Earnings registered a high of -$1.7 billion during Q1 2021, and its lowest value of -$3.7 billion during Q3 2025.
- Over the past 5 years, ImmunityBio's median Retained Earnings value was -$2.6 billion (recorded in 2023), while the average stood at -$2.7 billion.
- As far as peak fluctuations go, ImmunityBio's Retained Earnings crashed by 16299.69% in 2021, and later crashed by 1144.28% in 2025.
- Over the past 5 years, ImmunityBio's Retained Earnings (Quarter) stood at -$2.0 billion in 2021, then decreased by 21.23% to -$2.4 billion in 2022, then fell by 24.52% to -$3.0 billion in 2023, then decreased by 13.96% to -$3.4 billion in 2024, then dropped by 9.62% to -$3.7 billion in 2025.
- Its last three reported values are -$3.7 billion in Q3 2025, -$3.6 billion for Q2 2025, and -$3.5 billion during Q1 2025.